Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Chemotherapy for Locoregional Gastric/GEJ Adenocarcinoma
NCT02918162Phase 2Completed
- Start
- Nov 2017
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma. Primary endpoint: Pathologic Complete Response Rate up to 34 months. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02918162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918162.